6th Annual Gene Therapy for Ophthalmic Disorders Summit

6th Annual Gene Therapy for Ophthalmic Disorders Summit is organized by Hanson Wade and will be held from Dec 02 - 04, 2025 at DoubleTree by Hilton Raleigh Midtown, Raleigh, North Carolina, United States of America.

Unprecedented momentum is building in 2025:

• Kriya Therapeutics advancing through preclinical development
• Opus Genetics and SpliceBio entering their early trials
• Ocugen, 4D Molecular Therapeutics, and AbbVie racing towards BLA approval

This surge creates an urgent demand to mitigate critical bottlenecks like endpoints, funding, delivery, and more. The 6th Gene Therapy for Ophthalmic Disorders Summit returns to Raleigh, North Carolina, as the leading industry-specific event uniting biopharma scientists and strategists to tackle these challenges head-on. Join us to unlock the next breakthrough beyond Luxturna and accelerate your therapy to patients.

What is the 6th Gene Therapy for Ophthalmic Disorders Summit About?

With vision loss progressing rapidly in many eye diseases, and irreversible damage threatening patients with slower-onset conditions, gene therapies represent a critical one-time intervention to preserve sight.

The 6th Gene Therapy for Ophthalmic Disorders Summit brings together the latest breakthroughs driving this urgent field forward. This year's agenda features exclusive preclinical data from emerging leaders such as Opus Genetics, Coave Therapeutics, and Axovia Therapeutics, alongside 2025 clinical updates from Ocugen, Adverum Biotechnologies, and Beacon Therapeutics.

Don't miss groundbreaking data reveals and our dedicated focus on securing funding, advancing AAV delivery, and optimizing patient retention strategies - factors that are revolutionizing trial outcomes and shaping regulatory success

Speakers: Adam Turpcu, Senior Vice President - Clinical Development, Adverum Biotechnologies, Amy Christenson, Executive Director - Medical Affairs Lead, Beacon Therapeutics, Arun Upadhyay, Chief Scientific Officer, Ocugen, Ash Jayagopal, Chief Scientific and Development Officer, Opus Genetics, Christina Ohnsman, Chief Medical Officer, Tern Therapeutics, Claire Gelfman, Independent Expert, Darin Curtiss, Global Vice President - Clinical Development, Beacon Therapeutics, Hanen Khabou, Senior Scientist, SparingVision, James Kasuboski, Partner and Head of Research, Luma Group, Kenji Fujita, Chief Medical Officer, Atsena Therapeutics, Lolita Petit, Chief Scientific Officer, Coave Therapeutics, Moshe Weinstein, Executive Chairman, Everads Therapy Ltd, Paul Wille, Director, Product Development, Abeona Therapeutics, Philip Beales, CEO, Axovia Therapeutics, Randall Wong, Executive Director - Medical Affairs, 4D Molecular Therapeutics, Rob Lin, Chief Executive Officer, Avista Therapeutics, Sarah Tuller, Chief Regulatory Officer, Opus Genetics, Thomas Ciulla, President and Chief Executive Officer, Ikarovec